ライフサイエンスコーパス: aggressive

1 known about the mechanisms that make ESCC so aggressive.

2 pes: the germinal center B-cell-like and the aggressive activated B-cell-like (ABC) DLBCL.

3 rrant HOXA9 expression is a hallmark of most aggressive acute leukemias, notably those with KMT2A (ML

4 id metal electrodes with conductive gels and aggressive adhesives, while requiring precise positionin

5 tion in the perovskite absorber layer during aggressive aging.

6 ion of HCV+ hearts for transplantation, more aggressive allocation of HCV+ hearts at the OPO level ma

7 suggest that most male-directed mounting is aggressive, although in rare cases it can be sexual.

8 HER2-positive breast cancer are particularly aggressive and associated with unfavorable prognosis.

9 ival time with limited toxicity in mice with aggressive and chemoresistant diffuse intrinsic pontine

10 Glioblastoma multiforme (GBM) is an aggressive and difficult to treat form of brain cancer.

11 mous cell carcinoma (ESCC) is among the most aggressive and fatal cancer types.

12 hy (referred to as BLS-type DLBCL), which is aggressive and frequently associated with hemophagocytic

13 er childhood trauma, affective lability, and aggressive and impulsive traits predicted greater SI var

14 ients to long-term invasive surveillance, to aggressive and invasive tumors with high disease-specifi

15 As one of the most aggressive and lethal human malignancies with extremely

16 Young-onset breast cancers (YOBC) tend to be aggressive and may be etiologically different.

17 s to escape apoptosis, hence developing more aggressive and metastatic phenotypes.

18 In the majority of samples, however, these aggressive and potentially very damaging wood degraders

19 rge testes and bright coloration and perform aggressive and reproductive behaviors while nondominant

20 ctivating RAS mutations are typically highly aggressive and treatment-refractory, yet RAS mutation it

21 Emergence of an aggressive androgen receptor (AR)-independent neuroendoc

22 Despite aggressive antifungal therapies, outcomes of CNS cryptoc

23 m of increased thrombosis and the benefit of aggressive antithrombotic therapy in selected cases.

24 However, this aggressive approach has the reputation to be associated

25 n aggression-promoting (CAP) neurons mediate aggressive approach in both sexes, whereas functionally

26 dose AA and anti-PD1 agents in patients with aggressive B cell lymphoma as well as in preclinical mod

27 19 CAR T-cell therapy in people with HIV and aggressive B-cell lymphoma showed the feasibility of CAR

28 ival, and dissemination of cancer, including aggressive B-cell lymphoma.

29 he Food and Drug Administration for relapsed aggressive B-cell non-Hodgkin lymphoma in part on the ba

30 hyltransferase-5 (PRMT5) is overexpressed in aggressive B-cell non-Hodgkin's lymphomas, including man

31 s important for the regulation of inter-male aggressive behavior and provide the first functional evi

32 cea, Stomatopoda) are well studied for their aggressive behavior and unique visual system as well as

33 genome-wide association study of children's aggressive behavior and were used to calculate individua

34 y expressed in specific brain nuclei causing aggressive behavior in the white-throated sparrow.

35 Inter-male aggressive behavior is a prominent sexually dimorphic be

36 inant role of fru in specifying sex-specific aggressive behavior may underscore a genetic mechanism t

37 These results provide the evidence that aggressive behavior of radioresistant BC is caused by CD

38 re a genetic mechanism that allows male-type aggressive behavior to evolve at least partially indepen

39 Symptoms of depression and anxiety, aggressive behavior, and attention-deficit/hyperactivity

40 the neural circuit that generates male-type aggressive behavior.

41 Sexual and aggressive behaviors are fundamental to animal survival

42 ing domains show a division of labor on male aggressive behaviors.

43 f lorises in captivity, the function of this aggressive behaviour has never been studied in the wild

44 Inherent species recognition and higher aggressive behaviour may limit species coexistence as th

45 ime spent displaying and a divergence in the aggressive behaviour of the native species towards consp

46 cts on MAOA expression to regulate impulsive-aggressive behaviours.

47 breast cancer (TNBC) is characterized by its aggressive biology, early metastatic spread, and poor su

48 n requiring urgent treatment of mass effect, aggressive blood pressure reduction and correction of co

49 We have previously shown that the aggressive brain cancer, glioblastoma (GBM), maintains s

50 The aggressive brain tumor glioblastoma (GBM) is characteriz

51 treatment for glioblastoma, one of the most aggressive brain tumors that remains incurable despite a

52 ading to improved outcomes for children with aggressive brain tumors.

53 ioblastoma (GBM) is the most common and most aggressive brain tumour.

54 Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with a high

55 Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype.

56 iple negative breast cancer (TNBC), the most aggressive breast cancer subtype.

57 ated kinase (HUNK) kinase is up-regulated in aggressive breast cancers and is thought to play a role

58 In summary, aggressive cancer cell behaviour and reduced drug respon

59 A large number of aggressive cancer cell lines display elevated levels of

60 teins typify a proteotype associated with an aggressive cancer cell phenotype.

61 Cutaneous malignant melanoma is an aggressive cancer of melanocytes with a strong propensit

62 lmark in developing prostate lesions, and an aggressive cancer phenotype activating mechanisms allowi

63 TNBC is an aggressive cancer phenotype, with low 5-year survival ra

64 Triple-negative breast cancer (TNBC) is an aggressive cancer subtype for which effective therapies

65 Glioblastoma multiforme (GBM) is an aggressive cancer without currently effective therapies.

66 ement of patients suffering from this highly aggressive cancer.

67 An open question in aggressive cancers such as melanoma is how malignant cel

68 herapies can lead to an initial remission of aggressive cancers, they are often only a transient solu

69 ated with cell proliferation and invasion in aggressive cancers.

70 e, the cancer almost always recurs as a more aggressive castration resistant prostate cancer (CRPC).

71 s to hyperactivation of NFkB and a resultant aggressive cell type.

72 formed into a metastatic niche that captures aggressive circulating tumor cells.

73 arboring this methylation pattern had a more aggressive clinical course.

74 hough high mutation BCs were associated with aggressive clinical features, such as more frequent in E

75 ease morbidity and mortality by allowing for aggressive clinical management and glucocorticoid admini

76 reast cancer (BC) therapy is associated with aggressive clinical outcomes; thus, herein we present st

77 genomic profiles that may contribute to the aggressive clinical phenotypes seen in these patients.

78 ne variants that may partially explain their aggressive clinical phenotypes.

79 ecular mechanism underlying a case of highly aggressive colorectal cancer and illustrates the importa

80 domain of NRAS from a patient with extremely aggressive colorectal carcinoma.

81 enetic diversity was almost twice as high in aggressive compared with clinically favorable tumors (me

82 of hierarchical ascension in which the most aggressive, competitive, or coercive individuals rise to

83 In slightly more aggressive conditions, we observed transient accumulatio

84 lenging situation (i.e. physical exertion or aggressive context).

85 capsular invasion and tumor mass have a more aggressive course and a fatal outcome risk.

86 tion recognized entity, characterized by its aggressive course and poor prognosis.

87 of antithrombotic function, and with a more aggressive course of HCC and with a higher change of com

88 this work describes a new approach to target aggressive CSCs that may substantially improve clinical

89 ANCE Merkel cell carcinoma (MCC) is the most aggressive cutaneous tumor without clearly defined treat

90 Glioblastoma (GB) is a highly aggressive, difficult to treat brain tumour.

91 opulation, which may be associated with more aggressive disease and poorer outcome as compared to liv

92 resistant strains-may portend a more locally aggressive disease process or may represent preexisting

93 ons in human lung cancer and correlates with aggressive disease progression and poor patient prognosi

94 PEL is an aggressive disease with extremely poor prognosis when tr

95 enetic testing, especially in the setting of aggressive disease.

96 CA4 (BRG1) overexpression is associated with aggressive disease.

97 eased ploidy or aneuploid genomes that drive aggressive disease.

98 ors, and how their presence may give rise to aggressive disease.

99 tment and increase survival for men with the aggressive disease.

100 the performance of reproductive behavior and aggressive displays.

101 s in the oral/head & neck region (HNSCC) are aggressive due to high incidence of recurrence and dista

102 ations associated with resected indolent and aggressive early lung ADCs.Methods: DNA was extracted fr

103 significant yet underexplored coregulator in aggressive early stage PCa.

104 ypical teratoid/rhabdoid tumor (AT/RT) is an aggressive, early-childhood brain tumor without standard

105 he repeated experience of winning successive aggressive encounters across multiple days leads to incr

106 The data show that aggressive encounters between groups are initiated by fe

107 kers with biomineralized exoskeletons during aggressive encounters with other ants and reduced infect

108 This suggests that aggressive, environmentally independent PCa may be a res

109 Cip1) protein as a mechanism to maintain the aggressive epidermal SCC phenotype.

110 ~10% of diagnosed prostate cancer cases are aggressive, existing practice often results in overtreat

111 cells and achieves long-term survival in an aggressive experimental CRC liver metastasis model.

112 high tumors were associated with clinically aggressive features and "M1" high tumors enriched the ce

113 Here we investigate if decades of aggressive fire suppression in the boreal biome of Canad

114 ting a role for hemodynamic factors, such as aggressive fluid management.

115 These patients may require aggressive follow-up and/or adjuvant therapy to mitigate

116 98-PHF23 translocation is associated with an aggressive form of acute myeloid leukemia (AML) and poor

117 Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer characterized by metast

118 ular carcinoma (HCC) (MTM-HCC) represents an aggressive form of HCC and is associated with poor survi

119 s of Merkel cell carcinoma (MCC), a rare but aggressive form of human skin cancer, strongly suggestin

120 PEX glaucoma is a common, aggressive form of open-angle glaucoma resulting from th

121 l enable testing of novel therapies for this aggressive form of ovarian cancer.

122 Here, we model an aggressive form of prostate cancer and show the unconven

123 presenting Group 3 medulloblastoma, the most aggressive form of the disease.

124 idline carcinoma (NMC), is a rare and highly aggressive form of undifferentiated squamous cell carcin

125 of nonalcoholic fatty liver disease and its aggressive form, nonalcoholic steatohepatitis (NASH), re

126 ative breast cancer (TNBC) is among the most aggressive forms of breast cancer with limited therapeut

127 erican/black women, who tend to develop more aggressive forms of breast cancer.

128 -BRD4, were preferentially found in the more aggressive forms of breast cancers that lack well-define

129 e overexpression is commonly associated with aggressive forms of this disease.

130 e relapse, recurrence or progression to more aggressive forms.

131 members of the protein panel can distinguish aggressive from indolent cancers.

132 ht loss, this begs the question whether less aggressive gastric volume reduction may provide sufficie

133 scle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary malignancies.

134 ma or GBM has poor prognosis and is the most aggressive grade of glioma.

135 ted with a breakthrough of B cells and their aggressive graft infiltration.

136 indolence and subsequent transition back to aggressive growth include interactions with myeloid and

137 report that miR-211 expression promotes the aggressive growth of BRAF(V600E)-mutant melanoma xenogra

138 ession; another resulted from a fatal second aggressive head and neck squamous cell carcinoma diagnos

139 ell acute lymphoblastic lymphoma (T-LBL) are aggressive hematological malignancies that are currently

140 l acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with a dismal progno

141 beyond RB1 inactivation was associated with aggressive histopathologic features, including higher hi

142 y, these fusion-positive tumors exhibit more aggressive histopathological features, such as gross nec

143 ductal carcinoma of the prostate (IDC-P), an aggressive histopathological variant for which therapeut

144 study in 90 patients (45 per study arm) with aggressive HIV-NHLs, using dose-adjusted EPOCH (plus rit

145 ary, EPOCH had broad efficacy against highly aggressive HIV-NHLs, whereas vorinostat had no benefit;

146 utic opportunities for TNBC and other highly aggressive human cancers of epithelial origin.

147 n-coupled receptors that is downregulated in aggressive human prostate tumors.

148 Efficacy was tested using the very aggressive human triple negative breast cancer (TNBC, MD

149 re-existing p53-deficient tumors in a highly aggressive, immunocompetent mouse model of lung adenocar

150 conditioning regimens, in parallel with more aggressive immunosuppression to better control graft-ver

151 Here we describe an aggressive in vivo model of Toll-like receptor (TLR) 9 d

152 n aggression and suggest that, in subsets of aggressive individuals, domination of subordinate social

153 kly with high reliability and exhibit rapid, aggressive infiltration when transplanted into adult rod

154 k patients could permit early institution of aggressive intensive care and antiviral and immune treat

155 Early and aggressive interventions among this at-risk population c

156 Early and aggressive interventions are essential for improving cli

157 Consequently, aggressive interventions will likely be needed despite s

158 on and reef protection, to also include more aggressive interventions.

159 vaccines in several cancer models, including aggressive intracranial glioblastoma.

160 o are hormonally masculinized and frequently aggressive-is offset by their ability to maintain longer

161 Mesothelioma is highly aggressive; its sarcomatoid variants have worse prognosi

162 a and significantly improved survival in the aggressive KPC pancreatic cancer model.

163 tential utility of targeting ICMT to control aggressive KRAS-driven cancers.

164 crotic cores, to lesion regression following aggressive lipid lowering.

165 myofibroblasts and immune cells, followed by aggressive liver fibrosis.

166 enograft (PDOX) nude mouse model of a highly aggressive liver metastasis of colon cancer.

167 s toward therapeutic targeting of Yap/Taz in aggressive liver tumors marked by elevated Myc/beta-cate

168 mouse model revealed loss of Mst1/2 promotes aggressive lung adenocarcinoma and large-scale proteomic

169 itors, which results in recurrence of highly aggressive lung tumors.

170 lf-renewal properties, ultimately leading to aggressive lymphomas with an increased repopulating pote

171 The risk of misdiagnosis as more aggressive lymphomas, causing patient overtreatment, nee

172 Adrenocortical carcinomas (ACC) are rare and aggressive malignancies with limited treatment options.

173 cancer by 4-fold, identified all potentially aggressive malignancies, and allowed apparently safe non

174 ancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy that invades surrounding structure

175 Anaplastic thyroid carcinoma is an aggressive malignancy that is almost always fatal and la

176 Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy typified by a highly stromal and w

177 riple-negative breast cancer (TNBC)-a highly aggressive malignancy with a dismal posttreatment progno

178 is a genetically heterogeneous, biologically aggressive malignancy with a uniformly poor prognosis.

179 Hepatocellular carcinoma (HCC) is an aggressive malignancy with its global incidence and mort

180 Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with limited therapeutic options.

181 Neuroendocrine prostate cancer (NEPC) is an aggressive malignancy with no effective targeted therapi

182 Small cell lung cancer (SCLC) is a highly aggressive malignancy with poor outcomes associated with

183 s, suggesting a prompt identification and an aggressive management.

184 i-Harada syndrome, which was unresponsive to aggressive medical management.

185 The authors believe that the deployment of aggressive medical technology to win the "war" against t

186 signals that maintain immune suppression in aggressive melanomas.

187 MT and are highly expressed in patients with aggressive mesenchymal-like breast cancer.

188 The patients with aggressive metastatic disease or refractory/relapsed neu

189 ets-in cell and animal models confers a less aggressive/metastatic phenotype.

190 ing of the thoracic cavity leads to a highly aggressive MM that recapitulates the histological featur

191 Increased OTULIN levels are associated with aggressive molecular subtypes and poor survival in breas

192 celerated development of dementia and a more aggressive motor course.

193 n fused to IL-12 (CBD-IL-12) in mice bearing aggressive mouse tumours, CBD-IL-12 accumulates in the t

194 m, has a long-term survival of < 20% despite aggressive multimodality treatment.

195 nificant survival benefit in multiple highly aggressive murine models of SCLC, providing a rationale

196 Because of the rarity and aggressive nature of malignant thyroid mesenchymal tumou

197 one-sensitive lipase (HSL) in regulating the aggressive nature of pancreatic cancer.

198 inoma of the eyelid is an extremely rare but aggressive neoplasm diagnosed primarily in elderly men.

199 and frontotemporal dementia (FTD) constitute aggressive neurodegenerative pathologies that lead to th

200 logical transformation of adenocarcinomas to aggressive neuroendocrine derivatives - was initially de

201 Merkel cell carcinoma (MCC) is a highly aggressive neuroendocrine skin cancer with steadily incr

202 gn followed by routine vaccination alongside aggressive new vector control could enable short-term el

203 mab is the standard first-line treatment for aggressive non-Hodgkin lymphoma, and doxorubicin and cyc

204 s participating in the PET-Guided Therapy of Aggressive Non-Hodgkin Lymphomas trial, iPET scans of 59

205 We also assessed whether affective lability, aggressive or impulsive traits explain childhood trauma'

206 Many LGGs eventually transform into a more aggressive or malignant type.

207 subdivided as benign, intermediate (locally aggressive or rarely metastasising), and malignant.

208 outcomes of drug combinations in the highly aggressive orthotopic 4T1 murine breast cancer model.

209 Deletion of RGS12 exhibited aggressive OSCC in the tongue compared with the control

210 The proteome needed to support an aggressive osteosarcoma cell phenotype remains largely u

211 a chromatin regulator that is implicated in aggressive PCa.

212 iffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors for which there is cur

213 givitis (G), chronic periodontitis (CP), and aggressive periodontitis (AgP) based on clinical paramet

214 tion and contribute to greater osteolysis in aggressive periodontitis.

215 LVAD speed was optimized with an aggressive pharmacological regimen, and regular echocard

216 R2), are absent is known to express the most aggressive phenotype and increased metastasis which resu

217 Our results show that in birds of the more aggressive phenotype, ERalpha knockdown caused a phenoty

218 used a phenotypic change to that of the less aggressive phenotype.

219 tumors with high mutation rates demonstrate aggressive phenotypes and attract immune cells simultane

220 d Hopx(-/-) BM cells developed AML with more aggressive phenotypes compared with those transplanted w

221 poor disease-free survival and promotion of aggressive phenotypes in vitro and in vivo.

222 to iAs, because these tumors may spawn more aggressive phenotypes than unexposed ER+ tumors, in part

223 act make tumors more heterogeneous, increase aggressive phenotypes, and thus worsen patient outcomes.

224 uently, for differentiation of indolent from aggressive phenotypes.

225 y miRNAs that are differentially enriched in aggressive phenotypes.

226 n tumours of a higher stage or that are more aggressive, possibly linking the circadian clock to cell

227 mphocytes (leukopenia) characterize the most aggressive presentation.

228 The aggressive primary brain tumor glioblastoma (GBM) is cha

229 Glioblastomas are aggressive primary brain tumors known for their inter- a

230 EN gene signature that identified a group of aggressive primary PCas characterized by PTEN-del, high-

231 erized by tissue oxygen deficiency due to an aggressive proliferation of cancer cells.

232 iated with resistance to genotoxic stress in aggressive prostate cancer cells.

233 anges associated with NE differentiation and aggressive prostate cancer phenotype.

234 chondrial aconitase (ACO2) activity to favor aggressive prostate cancer.

235 Differentiating between indolent and aggressive prostate cancers (CaP) is important to decrea

236 survival as well as a higher probability for aggressive recurrence treatment.

237 In the SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial, atorv

238 nspecific songs and parasitic calls elicited aggressive responses from focal subjects and caused a do

239 er therapy, which may be beneficial for more aggressive ROP.

240 early disease recurrence are candidates for aggressive salvage treatment with high-dose chemotherapy

241 rve sheath tumors (MPNSTs), which are highly aggressive sarcomas that originate from cells of the Sch

242 ending the emissions curve, RCP8.5, the most aggressive scenario in assumed fossil fuel use for globa

243 Does being disagreeable-that is, behaving in aggressive, selfish, and manipulative ways-help people a

244 ionable therapeutic approach for a subset of aggressive SHH medulloblastomas characterised by reduced

245 Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the Merkel cel

246 erkel cell carcinoma (MCC) is a rare, highly aggressive skin cancer for which immune modulation by im

247 Malignant melanoma is an aggressive skin cancer with poor survival outcomes for p

248 However, deep ICHs are rare in some aggressive small vessel diseases that are characterized

249 fighting were therefore limited to specific aggressive social contexts.

250 the neuronal circuitry that underlies female aggressive social interactions and provides tools for th

251 find that phenotypically dominant males are aggressive, socially central, and that these males have

252 Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype.

253 ession from less aggressive subtypes to more aggressive states represent key targets for therapy.

254 Therapies targeting this aggressive subset of CTCs may merit exploration as poten

255 A highly aggressive subset of pancreatic ductal adenocarcinomas u

256 py (ADT), and it ultimately develops into an aggressive subset of this disease.

257 breast cancer (TNBC), as it remains the most aggressive subtype of breast cancer.

258 Small cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer that remains among the

259 CP provide new strategies for targeting this aggressive subtype of pancreatic cancer.

260 posterior fossa group A (PFA) being its most aggressive subtype.

261 pression of Prrx1 display the squamous, most aggressive, subtype of PDAC.

262 vary duct carcinoma (SDC) is one of the most aggressive subtypes of salivary gland cancers.

263 chanisms driving tumor progression from less aggressive subtypes to more aggressive states represent

264 ntributions of other factors (such as HIV or aggressive subtypes).

265 le identifying patients who may benefit from aggressive supportive care and early intervention.

266 anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma most commonly seen in childre

267 illustrates how combinatorial treatments for aggressive, T cell-deficient cancers can launch an antit

268 ng that CD70-deficient NOD mice develop more-aggressive T1D onset.

269 f developing metastases and may require more aggressive therapies.

270 ere modest and may reflect the need for more aggressive therapy.

271 d VCP expression was particularly induced in aggressive thyroid cancers and in patients who had poore

272 TRIM37 drives aggressive TNBC biology by promoting resistance to chemo

273 e of transcription and splicing and promotes aggressive TNBC phenotypes.

274 by the observed fight; bystanders were less aggressive toward fighters that were seen to initiate mo

275 This aggressive treatment causes large shifts in both circula

276 with improving therapeutic options and more aggressive treatment of elderly patients, will have majo

277 Early and aggressive treatment of TIC improves outcome.

278 erogeneous disease that often recurs despite aggressive treatment with neoadjuvant chemotherapy and (

279 ontent in patients with severe obesity, more aggressive treatments have been studied in this subgroup

280 antly, targeting TMPRSS13 expression renders aggressive triple-negative breast cancer cell lines high

281 a PDTX model, the majority of which display aggressive triple-negative IC10 gene activity.

282 between infiltration of mast cells and less aggressive tumor cell behavior.

283 ) primary mouse embryonic fibroblasts and in aggressive tumor growth in severe combined immunodeficie

284 her Hh ligand, by in vivo CRISPR led to more aggressive tumor growth suggesting that IHH, rather than

285 Colon cancer is the most aggressive tumor in both men and women globally.

286 vity positively correlates with increasingly aggressive tumor phenotypes and is predictive of recurre

287 ormation, accelerated tumor cell growth, and aggressive tumor phenotypes in the compound mice bearing

288 Cancer stem-like cells (CSC) induce aggressive tumor phenotypes such as metastasis formation

289 notherapy, metastatic melanoma represents an aggressive tumor type with a poor survival outcome.

290 nt pleural mesothelioma (MPM) is a rare, but aggressive tumor with dismal prognosis.

291 NA) in metastasis, using melanoma as a model aggressive tumor.

292 ve tobacco consumption likely generates more aggressive tumors at HPV-associated oropharynx subsites

293 vate-to-[1-(13)C]lactate conversion rates in aggressive tumors to enhanced glycolytic flux and lactat

294 an inhibitor and HIF-2alpha as a promoter of aggressive tumour behaviours, their roles in tumour onse

295 splasias that are likely to progress to more aggressive tumours.

296 sence of structural variants (SVs), the more aggressive type 2 pRCC and the rarer subtypes have numer

297 Triple-negative tumors are the most aggressive type of breast cancer.

298 docrine prostate cancer (NEPC), an extremely aggressive variant of castration-resistant prostate canc

299 Quality improvement strategies could include aggressive weaning protocols to increase the proportion

300 ackground Anaplastic thyroid cancer (ATC) is aggressive with a poor prognosis, partly because of the